Shanghai & Suzhou & Chengdu, China -- Immunofoco, a clinical-stage biotech company devoted to bringing revolutionary immune cell drugs to patients with solid tumors, announced a poster presentation at ASCO 2023 annual meeting for its preclinical CAR-T candidate based on Peri Cruiser^® Platform.

Peri Cruiser CAR-T: An Innovative Platform to Reduce On-Target Off- Tumor Toxicity of CAR-T Therapy (Poster #2539)

This poster showcases that the toxicity of on-target but off-tumor effects in CAR-T therapies has posed significant challenges and impeded the progress of CAR-T therapy, particularly for solid tumors. To address this issue, Immunofoco researchers have developed an innovative platform called Peri Cruiser^®. This platform utilizes shRNA technology and requires only a single lentiviral transfection to suppress the expression of multiple genes associated with CAR-T toxicities, while still allowing for the expression of designed CARs. By effectively reducing off-target toxicities in CAR-T therapy for solid tumors, PeriCruiser^® maintains the therapy's anti-tumor efficacy. Notably, PeriCruiser^® is a target-agnostic and cost-effective platform, which suggests its potential for broader applications in the development and clinical use of novel CAR-T therapeutics.

Immunofoco, a cutting-edge CAR-T company, is dedicated to addressing unmet clinical needs by advancing breakthroughs in CAR-T therapy for treating solid tumors as hematologic malignancies. Founded in fewer than three years, the company has achieved many milestones including four rounds of funding, totaling $50 million, a dual US and China IND CAR-T trial approval, an in-house CAR-T GMP manufacturing facility spanning 2,300 m² and three ongoing CAR-T clinical trials with encouraging results.